News Cantargia AB

Equities

CANTA

SE0006371126

Market Closed - Nasdaq Stockholm Other stock markets 08:59:44 29/04/2024 pm IST			5-day change	1st Jan Change
3.43 ^SEK	-0.58%		-8.04%	-8.24%

17/04	Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition	CI
10/04	Cantargia AB Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cantargia publishes Annual Report for 2023	18/04	AQ
Notice of annual general meeting in Cantargia AB (publ)	18/04	AQ
Cantargia publishes new data on the CAN10 antibody, detailing its interaction with IL1RAP and functional inhibition	17/04	AQ
Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition	17/04	CI
Cantargia : Proposal regarding share-based incentive scheme	15/04	PU
Cantargia : Proposal regarding guidelines for executive remuneration	15/04	PU
Cantargia AB Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal	10/04	CI
Cantargia publishes preclinical data on the potential of CAN10 in systemic sclerosis in a leading scientific journal	10/04	AQ
Cantargia AB Presents Unique Effects of Nadunolimab in Pancreatic Cancer	09/04	CI
Cantargia presents unique effects of nadunolimab in pancreatic cancer	09/04	AQ
Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis	02/04	CI
Cantargia publishes data highlighting the potential of CAN10 in atherosclerosis	02/04	AQ
Cantargia reports progress towards start of DOD-sponsored clinical trial of nadunolimab in leukemia	27/03	AQ
Cantargia AB Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia	27/03	CI
Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis	14/03	CI
Cantargia presents new human data further supporting CAN10 in the treatment of systemic sclerosis	14/03	AQ
Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer	06/03	CI
Cantargia reports new preclinical data on antitumor effects of nadunolimab in pancreatic cancer	06/03	AQ
Cantargia Q4 2023 - Progress with CAN10 and in PDA	23/02	AQ
Transcript : Cantargia AB, 2023 Earnings Call, Feb 22, 2024	22/02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cantargia AB

Equities

CANTA

SE0006371126

Summary

Filters